Caroverine inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats.
Comparable to the anti-craving compound acamprosate, caroverine reduces alcohol withdrawal symptoms by an antagonism at ionotropic glutamate receptors and a blockade of calcium channels. The present study examines the effect of caroverine in a craving model, in which acamprosate has proved effective before. A place aversion was induced by a conditioned morphine withdrawal by administration of the opioid antagonist naloxone (0.1 mg/kg, s.c.) 5-6 days after the subcutaneous implantation of a morphine pellet in rats. Testing in the drug-free state, the acquisition of a conditioned aversion against the naloxone-associated cues was inhibited by pretreatment with caroverine (5 mg/kg, i.p.). This result corroborates the involvement of excitatory glutamate and calcium in the development of conditioned withdrawal and craving. It offers further evidence for the hypothesis that these neuronal systems are altered during withdrawal in a similar way by ethanol and opiates.
Kratzer
U
U
Zoological Institute, Neuropharmacology, University of Tübingen, Auf der Morgenstelle 28E, D-72076 Tübingen, Germany.
Schmidt
W J
WJ
D000701:Analgesics, Opioid / Q000009:adverse effects*; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D003214:Conditioning, Classical / Q000187:drug effects*; D008297:Male; D009020:Morphine / Q000009:adverse effects*; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D011810:Quinoxalines; D009270:Naloxone; D009020:Morphine; C000957:caroverine